UPDATE 2-Alexion diversifies treatment portfolio with $1.41 bln Portola deal
May 05, 2020 at 08:45 AM EDT
Drugmaker Alexion Pharmaceuticals Inc on Tuesday agreed to buy Portola Pharmaceuticals Inc in a deal that values the smaller rival at $1.41 billion to gain access to a treatment for reversing the effects of blood thinners.
